financetom
Business
financetom
/
Business
/
Intel antisemitism lawsuit dismissed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intel antisemitism lawsuit dismissed
Feb 20, 2025 1:00 PM

NEW YORK, Feb 20 (Reuters) - A lawsuit in which a Jewish

former employee of Intel ( INTC ) accused the chipmaker of

firing him after he complained about an openly antisemitic

supervisor has been dismissed.

Lawyers for Intel ( INTC ) and the anonymous plaintiff John Doe, a

former vice president of engineering and onetime Israeli Defense

Forces soldier, filed a stipulation of dismissal on Thursday in

Manhattan federal court.

Doe's legal team included the Anti-Defamation League, in

that group's first lawsuit against a major Fortune 500 company

targeting antisemitism in the workplace.

It is unclear whether the parties settled. The dismissal was

with prejudice, meaning the case cannot be brought again.

According to the complaint, Intel ( INTC ) fired Doe last April in a

purported cost-cutting move not long after assigning him to

report to Alaa Badr, vice president of customer success and an

Egyptian native.

Doe said he was uncomfortable working with Badr, citing

Badr's support for anti-Israel online posts, including posts

cheering deaths of Israelis and IDF soldiers, and complaining

about "so many Israeli employees in our company."

Lawyers for Doe, Intel ( INTC ) and the other defendants did not

immediately respond to requests for comment.

Intel ( INTC ), based in Santa Clara, California, has said it has a

longstanding culture of diversity and inclusion, and does not

tolerate hate speech.

Doe had asked to maintain his anonymity, because revealing

his name could lead to harassment and physical violence, but a

judge rejected that request in October.

The judge said the emotionally and politically charged

nature of the case, and risk of further discrimination, did not

overcome "the people's right to know who is using their courts."

Doe had been appealing that decision.

The case is Doe v Intel Corp ( INTC ) et al, U.S. District Court,

Southern District of New York, No. 24-06117.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
X-energy raises $700 million to expand nuclear reactor projects in US
X-energy raises $700 million to expand nuclear reactor projects in US
Nov 24, 2025
Nov 24 (Reuters) - Nuclear reactor developer X-energy said on Monday it had closed a $700 million financing round led by trading company Jane Street to help expand its supply chain and commercial pipeline. WHY IT'S IMPORTANT The U.S. nuclear industry is undergoing a renaissance after years of stagnation, primarily driven by surging power demand from the so-called hyperscalers that...
Veeva Systems Expands Partnership With Roche Pharmaceuticals
Veeva Systems Expands Partnership With Roche Pharmaceuticals
Nov 24, 2025
08:12 AM EST, 11/24/2025 (MT Newswires) -- Veeva Systems ( VEEV ) said Monday that Roche Pharmaceuticals has extended its partnership with the company by integrating Veeva Vault CRM, a deep application for life sciences. Financial terms of the expanded partnership were not disclosed. The Vault CRM platform includes Veeva AI, which features industry-specific AI agents, including Free Text Agent,...
Trubar Q3 Revenue Jumps 88%
Trubar Q3 Revenue Jumps 88%
Nov 24, 2025
08:13 AM EST, 11/24/2025 (MT Newswires) -- Trubar ( TRBRF ) said Monday that third-quarter net revenue and adjusted EBITDA both advanced. The company, which manufactures plant-based protein products, said net revenue jumped 88% to US$21.6 million. Adjusted EBITDA rose to $1.4 million from the $1 million in the previous corresponding quarter. Trubar ( TRBRF ) reaffirmed its full year...
Arrowhead Pharmaceuticals to Receive $200 Million Payment From Sarepta Therapeutics for Meeting ARO-DM1 Milestone
Arrowhead Pharmaceuticals to Receive $200 Million Payment From Sarepta Therapeutics for Meeting ARO-DM1 Milestone
Nov 24, 2025
08:13 AM EST, 11/24/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Monday that it has earned a $200 million milestone payment from Sarepta Therapeutics ( SRPT ) for meeting a second development milestone event in a phase 1/2 clinical study of ARO-DM1 to treat type 1 myotonic dystrophy. Under the terms of the license and collaboration deal between...
Copyright 2023-2026 - www.financetom.com All Rights Reserved